$RLAY News
Last published 1w ago
- 1w agoRLAYRelay Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoRLAYRelay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate UpdatesGlobeNewswirePhase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at
- 1w agoRLAYRelay Therapeutics to Participate in Three Upcoming Investor Conferences in NovemberGlobeNewswireCAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients
- 2w agoRLAYRelay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026GlobeNewswireCAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients
- 1mo agoRLAYRelay Therapeutics - Morgan Stanley 24th Annual Global Healthcare Conference - RELAY THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I'm so happy to be joined by the management team of Relay Therapeutics on the last day of the Morgan Stanley Healthcare Conference. I am joined here by President and CEO Sanjeev Patel, President o
- 2mo agoRLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberGlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients
- 3mo agoRLAYRelay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate UpdatesGlobeNewswireSelected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented
- 3mo agoRLAYRelay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026GlobeNewswireCAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients
- 3mo agoHYFTSDGRABCLRLAY+1An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the NumbersPR NewswireFor years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can talk...
- 5mo agoRLAYGoldman Sachs 47th Annual Global Healthcare Conference - Goldman SachsEarnings Call TranscriptsGood morning, everyone. It's my pleasure to introduce the Relay Management Team. Next to me, I have Sanjeev Patel, President and CEO, and Peter Rahmer, Chief Corporate Development Officer. Thank you for joining us. To st
- 5mo agoRLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneGlobeNewswireCAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
- 5mo agoRLAYRelay Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
- 5mo agoRLAYRelay Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
- 5mo agoRLAYRelay Therapeutics Conference Call: Initial Clinical Data for Zovegalisib in Vascular AnomaliesRELAY THERAPEUTICS INCEarnings Call TranscriptsGood day, ladies and gentlemen. Welcome to Relay Therapeutics Vascular Anomalies Update Call. As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Mr. Pet
- 5mo agoRLAYRelay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular AnomaliesGlobeNewswirePromising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported
- 6mo agoRLAYRelay Therapeutics Reports First Quarter 2026 Financial Results and Corporate UpdatesGlobeNewswireFDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase
- 6mo agoRLAYRelay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026GlobeNewswireCAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients
- 6mo agoRLAYRelay Therapeutics Conference Call: Zovegalisib Triplet Data in Breast Cancer - RELAY THERAPEUTICS INCEarnings Call TranscriptsGood day, ladies and gentlemen, and welcome to the Relay Therapeutics Frontline Breast Cancer Update Call. As a reminder, this conference call is being recorded. I would now like to introduce your host for today's confer
- 6mo agoRLAYRelay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast CancerGlobeNewswireZovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated,
- 7mo agoRLAYRelay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026GlobeNewswireCAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients
- 8mo agoRLAYRelay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026GlobeNewswire400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Efficacy
- 8mo agoRLAYBarclays 28th Annual Global Healthcare ConferenceRELAY THERAPEUTICS INCEarnings Call TranscriptsHello again, everyone. My name is Edson DeRute, one of the senior biotech analysts at Barclays. It's my pleasure to have our next fireside chat with Relay Therapeutics. With us this morning, we have Sanjay Patel, CEO of
- 8mo agoCMPXMRKSGENPFE+8Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightPR NewswireThe biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing...
- 8mo agoRLAYRelay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 MilestonesGlobeNewswireInitial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial
- 8mo agoRLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in MarchGlobeNewswireCAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
- 8mo agoRLAYRelay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026GlobeNewswireCAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
- 9mo agoONCYRLAYMAIAZLAB+1$207B Market Shift: The Race for Fast Track Approval in OncologyPR NewswireUSANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued...
- 9mo agoRLAYRelay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireCAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
- 9mo agoRLAYRelay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast CancerGlobeNewswireDesignation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the
- 11mo agoCNTXIMNMONCYPRLD+1Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval StandardsGlobeNewswireVANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster
- 11mo agoRLAYRelay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025GlobeNewswireEfficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated,
- 1y agoRLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in NovemberGlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
- 1y agoRLAYRelay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025GlobeNewswireCAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
- 1y agoRLAYRelay Therapeutics, Inc. (RLAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoRLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberGlobeNewswireCAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living
- 1y agoRLAYRelay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate UpdatesGlobeNewswirePresented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in
- 1y agoRLAYRelay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025GlobeNewswireCAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
- 1y agoONCYIMRXGRALINTS+1With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in OncologyPR NewswireUSA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor ...
- 1y agoBCAXRLAYRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
- 1y agoRLAYRelay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025GlobeNewswireUpdated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation
- 1y agoRLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneGlobeNewswireCAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and
- 1y agoBFLYATRAZNRLAYHealthcare's Quiet AI Boom Is Creating a New Class of Breakout ContendersPR NewswireEquity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark...
- 1y agoRLAYRelay Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and
- 1y agoRLAYRelay Therapeutics Reports First Quarter 2025 Financial Results and Corporate UpdatesGlobeNewswireCash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the
- 1y agoRLAYRelay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025GlobeNewswireCAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
- 1y agoBNTXGSKNVSRLAY+2Barbara Weber, M.D., Elected to ITM Supervisory BoardGlobeNewswireGarching / Munich, Germany, April 09, 2025 –
- 1y agoRLAYRelay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesGlobeNewswireInitiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 +
- 1y agoRLAYRelay Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
- 1y agoRLAYRelay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025GlobeNewswireCAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
- 1y agoRLAYRelay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational